Page 2490 - Williams Hematology ( PDFDrive )

2461
2460 Index Index 2461

MACOP-B regimen interaction with coagulation cascade, MAGT1, 1221
for anaplastic large cell lymphoma, 1699 1059 Major basic protein (MBP), 929, 948, 952
for diffuse large B-cell lymphoma, 1630 motility, 1059 Major cytogenic response (MCyR), 1452t
for primary mediastinal large B-cell recognition and clearance, 1060 Major histocompatibility complex (MHC),
lymphoma, 1634 hematopoietic functions, 1071 2353, 2354f, 2355. See also Human
Macrocyte, 21 immunomodulation of phenotype, 1070t leukocyte antigen (HLA)
Macrocytic anemia, 506 iron released from, 551 Major histocompatibility complex (MHC)
Macrocytosis, 559, 654, 655 M1 and M2 phenotypes, 284, 285 class I, 409, 1141, 1177, 1190
α -Macroglobulin, 1960–1961, 2308 markers, 1080t Major histocompatibility complex (MHC)
2
Macroglobulinemia. See Waldenström marrow, 32t, 34 class I deficiency, 1215t, 1221
macroglobulinemia morphology, 1048–1052, 1050f, 1051f Major histocompatibility complex (MHC)
Macroglossia, 5, 1774, 1775f neonatal, 108–109 class II, 1141, 1177, 1214t, 1978
Macrophage activation syndrome, production Major histocompatibility complex (MHC)
1115–1116, 1539 development, 1075–1076 class II deficiency, 1215t, 1221
Macrophage colony-stimulating factor growth, differentiation, and turnover, Major molecular response (MMR), 1452t
(M-CSF), 62t, 249, 1077–1078, 1076, 1076f MAL (MyD88 adapter-like), 297f, 298
1077f in hematopoietic organs, 61 Malaise, history of, 4
Macrophage inflammatory protein (MIP)-1α, maturation and differentiation, Malaria, 815–818
288t, 1440, 1737–1738, 1738f, 1739f 1077–1078, 1077f alterations in infected red cell, 815–816
Macrophage inflammatory protein (MIP)-1β, receptors blood antigens associated with resistance
288t CD4, 1056–1057 to, 2340
Macrophage receptor with collagenous CD11, 1056 Burkitt lymphoma and, 1573, 1672
structure (MARCO), 1055, 1057t, CD14, 1056 clinical features, 817
1080, 1082, 1084, 1085f CD16, 1056 course and prognosis, 818
Macrophages chemokine, 1057–1058, 1058t diagnostic methods, 817–818, 817f
activation, 283, 1083–1086 complement, 1054 epidemiology, 815
classical and alternative, 1085–1086, Fc, 1053–1054, 1053f G6PD deficiency and, 690
1086f human leukocyte antigen class II, glycoprotein IV deficiency and, 2359
immunomodulation, 1084, 1085f 1055–1056 pathogenesis, 816–817
innate, 1084–1085 non–toll-like, nonopsonic, 1054–1055, Plasmodium spp. and severity of anemia
in response to inflammation and 1056f, 1057t in, 816
tumors, 1083–1084, 1084f surface, 1052–1053, 1058t prevention, 818
in atherothrombosis, 2287 surface antigens, 1052f pyruvate kinase deficiency and, 704
blood dendritic cells and, 1092 toll-like, 1054, 1055f red cell exchange for, 432
disorders, 1089, 1090t. See also Monocytes, resident populations in adult tissues, sickle cell trait and, 763
disorders 1079–1080, 1080t Southeast Asian ovalocytosis and, 680
distribution secretion products, 1067t thalassemias and, 728
in central nervous system, 1083 stromal, 1082f, 1083f treatment, 818
in lymph nodes, 1082 study methods, 1075 Malignancy. See Cancer
in marrow, 1081–1082, 1082f, 1083f Macroreticulocytes, 467 Malignant fibrous histiocytoma, 1110
in nonlymphohematopoietic organs, MAdCAM-1 (mucosal addressin cell Malignant hypertension, 2263
1082–1083 adhesion molecule 1), 950, 1977 Malignant transformation, 132
in spleen, 90–91, 1082 MAF (MAF), 233t, 1713, 1736, 1736t MALT (mucosa-associated lymphoid tissue),
functions MAG (myelin-associated glycoprotein), 93–94
apoptosis, 1060–1061, 1061f 1790 MALT lymphoma. See Extranodal marginal
cell adhesion and homing, 66 MAGE-1, 412 zone lymphoma of MALT type
cellular interactions, 1066, 1071, 1071f Magnesium sulfate, for sickle cell disease, Mammalian target of rapamycin (mTOR),
in chronic inflammation, 284, 291 777t 194, 1654, 2237, 2237f
endocytosis, phagocytosis, and killing, Magnesium transporter 1 defects, 1221 Mammalian target of rapamycin (mTOR)
1061–1063, 1062f, 1063f, 1064f, Magnetic resonance imaging (MRI) inhibitors, 1220, 1403. See also
1065f in cardiac amyloidosis, 1779, 1780f Temsirolimus
gene expression, synthesis, and for marrow evaluation, 659 Mannan-binding lectin (MBL) pathway, 289f,
secretion, 1064–1066, 1067t, 1068f, in myeloma, 1715, 1748, 1749f 290
1069f, 1070f, 1070t for pulmonary embolism, 2271–2272 Mannose-binding lectin (MBL), 1017
G-protein-coupled receptors and, 1060t in Waldenström macroglobulinemia, Mannose receptors (MRs), 284, 1054, 1057t,
inflammasome, 1063, 1065f, 1066f 1792 1080, 1081f

Kaushansky_index_p2393-2506.indd 2461 9/21/15 3:22 PM